Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This is a Phase 2/3 study to evaluate the safety and efficacy of 2 different dose concentrations of OTX-101 dosed twice a day in both eyes for 84 days compared to placebo (vehicle) in patients with keratoconjunctivitis sicca (dry eye disease).
Epistemonikos ID: 51b90a1a014a30139aca2a6392f6350adcaa8c94
First added on: May 12, 2024